N@N

Anacor Pharmaceuticals to Present at the Stifel Nicolaus 2011 Healthcare Conference

_{//health-fitness.news-articles.net/content/2011/ .. -stifel-nicolaus-2011-healthcare-conference.html}
^{Published in Health and Fitness on Friday, September 2nd 2011 at 11:23 GMT by Market Wire}  

PALO ALTO, Calif.--([ BUSINESS WIRE ])--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that David Perry, the companya™s Chief Executive Officer, will provide a company overview at the Stifel Nicolaus 2011 Healthcare Conference at 3:50 p.m. ET on Thursday, September 8, 2011 in Boston, Massachusetts. The presentation will be webcast live and may be accessed under aEvents and Presentationsa on the Investors page of Anacora™s website at [ www.anacor.com ]. A replay will also be available for three months following the presentation.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered five compounds which are currently in clinical development, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis and atopic dermatitis; and GSK 2251052, or GSK a052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. For more information visit [ http://www.anacor.com ].